You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Identification of RORg drug candidates for the treatment of NASH
SBC: VISIONARY PHARMACEUTICALS, INC. Topic: 300ABSTRACT Significance An epidemic proportion of Americans approximately million suffer from obesity and nonalcoholic fatty liver disease a spectrum of progressive liver disease that include steatosis non alcoholic steatohepatitis NASH fibrosis and eventually cirrhosis and hepatocellular carcinoma HCC There is no standard of care pharmacotherapy for NASH Therefore new thera ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease
SBC: AVEXEGEN THERAPEUTICS INC. Topic: 300ABSTRACT Inflammatory Bowel Disease IBD is a collective name for Crohn s Disease and Ulcerative Colitis UC Both conditions manifest with a pathological inflammation of the bowel that causes breaks in mucosal integrity frank ulceration and the risk of more severe complications While the etiology of IBD is complex and not fully understood the two distinguishing hallmarks of IBD are dysregula ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small molecule activators of alpha crystallin for non surgical treatment of cataracts
SBC: Plex Pharmaceuticals, Inc. Topic: NProject Summary Cataract the clouding of the eye lens is responsible for of world blindness According to World Health Organization nearly million people are bilaterally blind from cataract in the world Cataract is easily treated by surgery and is considered as one of the most cost effective interventions Although cataract surgery is generally considered to be safe there are significan ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Rapid and sensitive detection of TB in non-sputum samples and paucibacillary pleural fluid using a novel non-enzymatic isothermal assay platform to enable routine childhood TB screening
SBC: GenEndeavor LLC Topic: NICHDProject Summary Objectives The long term objective of this application is to develop novel assays panels and kits to enable rapid and early point of care POC testing of TB in children The envisioned POC test would be administered in home by mothers to their children and in local healthcare centers by community healthcare workers who can diagnose and begin treatment of children with TB withi ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Multiplexed Point Of Care Nucleic Acid Assay for STI
SBC: PHOENIX BIOSYSTEM, INC. Topic: NIBIBDESCRIPTION provided by applicant With nearly million new infections annually sexually transmitted diseases STDs are very common in the United States And with recent changes to the national health care landscape including the passage of the Affordable Care Act and state budget cuts resulting in the closure of STD and HIV clinics primary care providers can expect to encounter more patie ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Near patient molecular diagnostics test for infections
SBC: GeneFluidics, Inc. Topic: RABSTRACT Currently there are no FDA cleared molecular based tests for urinary tract infection UTI pathogen identification and antimicrobial susceptibility testing to replace the andapos gold standardandapos of dipstick urinalysis and urine culturing All pathogen identification tests still rely on clinical isolates from urine cultures largely unchanged from Kochandapos s postulates developed ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application
SBC: EYENUK, INC. Topic: NEIAbstract In this Commercialization Readiness Pilot CRP Program application we propose to commercialize and bring to market EyeArt a fully automated high throughput retinal image analysis based diabetic retinopathy DR screening tool which has been developed and already validated in bench tests on very large real world data by developing and executing a market access plan conducting a pi ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Isothermal Chain Reaction (ICR) Rapid and Early Detection of Pathogens for Sepsis Pont-of-Care Testing, Stratification, and Monitoring
SBC: GenEndeavor LLC Topic: NIAIDProject Summary Objectives The long term objective of this application is to develop novel products for routine point of care POC genetic testing ranging from pathogen identification to early cancer detection by using an innovative biotechnology called Isothermal Chain Reaction ICR ICR is a disruptive and enabling technology platform that will offer a new class of reagents relevant to biom ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
SBC: BIOVINC, LLC Topic: RDESCRIPTION provided by applicant Bone and joint infections affect millions of adults and children worldwide The overall incidence in the United States is million persons with specific populations having different risks For example in diabetic patients have foot ulcers and up to two thirds of these have osteomyelits The standard of care for bone and joint infections includes prol ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Chikungunya Recombinant Subunit Vaccine
SBC: HAWAII BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant Chikungunya virus CHIKV is an alphavirus classified as a category C priority pathogen that causes fever rash and arthralgia in humans In the past decade CHIKV outbreaks have spread beyond the endemic regions of Africa and Asia first to the islands in the Indian Ocean and most recently to the Americas The World Health Organization has reported that as ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health